

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT SHARE PURCHASE PURSUANT TO THE SHARE AWARD SCHEME

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

References are made to the announcement (the “**Announcement**”) of the Company dated August 28, 2024 in relation to the adoption of the share award scheme (the “**Scheme**”) by the board (the “**Board**”) of directors (the “**Director(s)**”) of the Company and the announcement of the Company dated November 18, 2024 in relation to the share purchase by the Trustee pursuant to the Scheme. Unless otherwise stated, capitalized terms used in this announcement shall have the same meanings as defined in the Announcement.

The Company was informed by the Trustee that, from November 19, 2024 to January 23, 2025, the Trustee has used approximately HK\$12.78 million to purchase 1,322,400 Shares in aggregate (representing approximately 0.89% of the total number of Shares in issue as at the date of this announcement) on the market at an average consideration of approximately HK\$9.67 per Share. As of the date of this announcement, the Trustee has used approximately HK\$17.92 million in aggregate to purchase a total of 1,799,600 Shares pursuant to the Scheme, representing approximately 1.22% of the total number of Shares in issue as at the date of this announcement. The Shares so purchased will be used as Awards to the Eligible Participants under the Scheme to incentivize them to make contribution to the Group. In addition, the Shares purchased also demonstrates the Company’s confidence in its business outlook and prospect.

The Trustee will continue to purchase the Shares on the market pursuant to the rules of the Scheme. The Company will comply with the Listing Rules requirements when it decides to grant any Award pursuant to the Scheme in the future.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, January 23, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.